Imprinting Defects in Osteosarcoma: DNA- and Chromatin-Modifying Drugs Hold Promise for Osteosarcoma Therapy

References

• Allison DC , CarneySC , AhlmannERet al. A meta-analysis of osteosarcoma outcomes in the modern medical era . Sarcoma2012 , 704872 ( 2012 ).
   PubMedGoogle Scholar
• Shu J , LiL , SarverAEet al. Imprinting defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma . Oncotarget doi:10.18632/oncotarget.6965 ( 2016 ) ( Epub ahead of print ).
   Google Scholar
• Riggs AD . X chromosome inactivation, differentiation, and DNA methylation revisited, with a tribute to Susumu Ohno . Cytogenet. Genome Res.99 ( 1–4 ), 17 – 24 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Holliday R , PughJE . DNA modification mechanisms and gene activity during development . Science187 ( 4173 ), 226 – 232 ( 1975 ).
   PubMed Web of Science ®Google Scholar
• Horvath S , ErhartW , BroschMet al. Obesity accelerates epigenetic aging of human liver . Proc. Natl Acad. Sci. USA111 ( 43 ), 15538 – 15543 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Paul B , BarnesS , Demark-WahnefriedWet al. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases . Clin. Epigenetics7 , 112 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Polak P , KarlicR , KorenAet al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer . Nature518 ( 7539 ), 360 – 364 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Solary E , BernardOA , TefferiA , FuksF , VainchenkerW . The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases . Leukemia28 ( 3 ), 485 – 496 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• NIH Roadmap Epigenomics Consortium . www.roadmapepigenomics.org .
   Google Scholar
• Friedman N , RandoOJ . Epigenomics and the structure of the living genome . Genome Res.25 ( 10 ), 1482 – 1490 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Teschendorff AE . Computational and Statistical Epigenomics . Springer , The Netherlands ( 2015 ).
   Google Scholar
• Kundaje A , MeulemanW , ErnstJet al. Integrative analysis of 111 reference human epigenomes . Nature518 ( 7539 ), 317 – 330 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Aran D , SabatoS , HellmanA . DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes . Genome Biol.14 ( 3 ), R21 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lin S , GregoryRI . MicroRNA biogenesis pathways in cancer . Nat. Rev. Cancer15 ( 6 ), 321 – 333 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• De Nigris F . Epigenetic regulators: Polycomb-miRNA circuits in cancer . Biochim. Biophys. Acta1859 ( 5 ), 697 – 704 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Thayanithy V , SarverAL , KarthaRVet al. Perturbation of 14q32 miRNAs–cMYC gene network in osteosarcoma . Bone50 ( 1 ), 171 – 181 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Chen J , GuoL , ZhangLet al. Vitamin C modulates TET1 function during somatic cell reprogramming . Nat. Genet.45 ( 12 ), 1504 – 1509 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Krishnadas DK , ShustermanS , BaiFet al. A Phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma . Cancer Immunol. Immunother.64 ( 10 ), 1251 – 1260 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Fang F , MunckJ , TangJet al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer . Clin. Cancer Res.20 ( 24 ), 6504 – 6516 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kuang Y , El-KhoueiryA , TavernaP , LjungmanM , NeamatiN . Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin . Mol. Oncol.9 ( 9 ), 1799 – 1814 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Xia C , Leon-FerreR , LauxDet al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide) . Cancer Chemother. Pharmacol.74 ( 4 ), 691 – 697 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Vendetti FP , TopperM , HuangPet al. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer . Oncotarget6 ( 1 ), 56 – 70 ( 2014 ).
   Google Scholar
• Ranganathan P , YuX , SanthanamRet al. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia . Blood125 ( 17 ), 2689 – 2692 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Thayanithy V , ParkC , SarverALet al. Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines . PLoS ONE7 ( 9 ), e43720 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Li B , ZhuX , SunLet al. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma . Oncotarget5 ( 21 ), 10791 – 10802 ( 2014 ).
   PubMedGoogle Scholar
• Krishnadas DK , BaoL , BaiF , ChencheriSC , LucasK . Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1 . Tumour Biol.35 ( 6 ), 5753 – 5762 ( 2014 ).
   PubMedGoogle Scholar
• Liu T , ShenJK , LiZ , ChoyE , HornicekFJ , DuanZ . Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma . Cancer Lett.373 ( 1 ), 109 – 118 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Vojta A , DobrinicP , TadicVet al. Repurposing the CRISPR-Cas9 system for targeted DNA methylation . Nucleic Acids Res. doi:10.1093/nar/gkw159 ( 2016 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar